Shilpa Medicare has received approval from the US health regulator for generic Capecitabine tablets used for treatment of various types of cancers.
The company has received an approval from the United States Food and Drug Administration (USFDA) for Capecitabine tablets USP in the strengths of 150 mg and 500 mg, Shilpa Medicare said in a BSE filing.
The product is a generic version of Hoffmann-La Roche Inc's Xeloda tablets in the same strengths, it added.
Capecitabine tablets are used to treat breast and colorectal cancers. It works by slowing or stopping the growth of cancer cells.
Shares of Shilpa Medicare were trading 1.94 per cent up at Rs 673.25 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
